Trovagene has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology, MIT, under which Trovagene has exclusive rights to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase inhibitor for the treatment of cancer. The exclusive license agreement is part of the company’s strategy to explore the efficacy of Onvansertib, its oral PLK1 inhibitor, in combination with anti-androgen drugs in cancers including prostate, breast, pancreatic, lung and gastrointestinal. In this Phase 2 trial, Onvansertib in combination with the standard dose of Zytiga and prednisone is being evaluated for safety and efficacy. The trial will enroll up to 45 patients with mCRPC showing early signs of disease progression. The primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks of study treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.